Open Government Portal
MaintenanceWe are performing scheduled maintenance from 8:00am to 12:00pm, Monday, December 4th, Eastern time.
Loss of control and collision with water, True North Airways Inc., de Havilland DHC-3 Otter, C-FDDX, Pluto Lake, Quebec, 12 October 2022
Hard landing, Range Helicopters Inc., Airbus Helicopters AS350 B2 (helicopter), C-FAVX, Edson Airport (CYET), Alberta, 04 May 2023
Health Canada, through its Clinical Trials Database, is providing to the public a listing of specific information relating to phase I, II and III clinical trials in patients. The database is managed by Health Canada and provides a source of information about Canadian clinical trials involving human pharmaceutical and biological drugs.
Collision with vehicle and terrain, Privately registered, Cessna 182P, C-GIDY, Langley Regional Airport, British Columbia, 02 May 2023
Through SAP, health care professionals may request access to drugs that are not currently authorized for sale in Canada to treat patients with serious or life-threatening conditions. Access to these drugs is only considered when conventional therapies have failed, are unsuitable or are unavailable.
If you're a health care professional, you can request a drug that is not available for sale in Canada through the Special Access Program (SAP).
With Financial Performance Data you can view financial data based on industry averages.
This guidance document is specific to the "tamper-resistance" feature of controlled-release opioid products. It is intended for the pre-market review of drug submissions when sponsors seek to obtain approval for controlled-release opioid drug formulations with tamper-resistant properties and wish to include, in product monographs, scientific statements and claims regarding tamper-resistance.
Through its Action Plan on Medical Devices, Health Canada is committed to continuing to provide Canadians with more information on the medical devices they use. The Department is pleased to announce that it will begin publishing Regulatory Decision Summaries (RDSs) for all new Class III medical device licences (e.g. orthopedic implants or blood glucose monitors) starting January 31, 2019.
2023 ESDC progress report on how we are meeting the Accessible Canada Act and Regulations